Drug Trial Radar · NCT05681299
Effects of GH and Lirglutide on AgRP
Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
May 1, 2023
Primary completion
Apr 30, 2028
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Columbia UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglutide, iii) liraglutide alone and iv) placebo. Each phase of the study will consist of a 7-day baseline period including 2 days of testing and 21 days on therapy with visits on days 2, 7, 14 and 21. Testing before, during and at the completion of each arm will include blood sampling and assessments of insulin resistance, energy expenditure and body composition.
Conditions
- Healthy
- Growth Hormone Deficiency
Interventions
growth hormone and lirglutideDrug
GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
growth hormoneDrug
GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.
liraglutideDrug
Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
PlaceboDrug
Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AgRP change in GH vs. placebo armsTime frame: Baseline to weeks 1, 2, 3 of each study arm.
- AgRP change in GH vs. GH + liraglutide armsTime frame: Baseline to weeks 1, 2, 3 of each study arm.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.